Evidence map›Paper›PMID 25340701›Full record

SynthesisPloS one2014

Modeling of novel diagnostic strategies for active tuberculosis - a systematic review: current practices and recommendations.

Alice Zwerling, Richard G White, Anna Vassall, Ted Cohen, David W Dowdy, Rein M G J Houben

Abstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Clinical Impact and Cost-effectiveness of Xpert MTB/RIF Testing in Hospitalized Patients With Presumptive Pulmonary Tuberculosis in the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2017
    Article
  9. Article
  10. Article
  11. The Point-of-Care Laboratory in Clinical Microbiology.Clinical microbiology reviews · 2016
    Review
  12. Article
  13. Article
  14. Bridging the gap between evidence and policy for infectious diseases: How models can aid public health decision-making.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2016
    Review
  15. Article
  16. Article
  17. Diagnostics of tuberculosis and differentiation of nonspecific tuberculin reactions in animals.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Alice ZwerlingDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
Richard G WhiteTB Modelling Group, TB Centre, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Anna VassallDepartment of Global Health and Development, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Ted CohenDepartment of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, United States of America.
David W DowdyDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
Rein M G J HoubenTB Modelling Group, TB Centre, London School of Hygiene and Tropical Medicine, London, United Kingdom.

Funding

CIHRMedical Research Council G0802414Medical Research Council MR/J005088/1
6 · The paper itself

Abstract

introductionThe field of diagnostics for active tuberculosis (TB) is rapidly developing. TB diagnostic modeling can help to inform policy makers and support complicated decisions on diagnostic strategy, with important budgetary implications. Demand for TB diagnostic modeling is likely to increase, and an evaluation of current practice is important. We aimed to systematically review all studies employing mathematical modeling to evaluate cost-effectiveness or epidemiological impact of novel diagnostic strategies for active TB.

methodsPubmed, personal libraries and reference lists were searched to identify eligible papers. We extracted data on a wide variety of model structure, parameter choices, sensitivity analyses and study conclusions, which were discussed during a meeting of content experts. RESULTS & DISCUSSION: From 5619 records a total of 36 papers were included in the analysis. Sixteen papers included population impact/transmission modeling, 5 were health systems models, and 24 included estimates of cost-effectiveness. Transmission and health systems models included specific structure to explore the importance of the diagnostic pathway (n = 4), key determinants of diagnostic delay (n = 5), operational context (n = 5), and the pre-diagnostic infectious period (n = 1). The majority of models implemented sensitivity analysis, although only 18 studies described multi-way sensitivity analysis of more than 2 parameters simultaneously. Among the models used to make cost-effectiveness estimates, most frequent diagnostic assays studied included Xpert MTB/RIF (n = 7), and alternative nucleic acid amplification tests (NAATs) (n = 4). Most (n = 16) of the cost-effectiveness models compared new assays to an existing baseline and generated an incremental cost-effectiveness ratio (ICER).

conclusionAlthough models have addressed a small number of important issues, many decisions regarding implementation of TB diagnostics are being made without the full benefits of insight from mathematical models. Further models are needed that address a wider array of diagnostic and epidemiological settings, that explore the inherent uncertainty of models and that include additional epidemiological data on transmission implications of false-negative diagnosis and the pre-diagnostic period.

Indexed as

Diagnostic Techniques and ProceduresPractice Patterns, Physicians'Cost-Benefit AnalysisHealth Planning GuidelinesHumansModels, TheoreticalTuberculosis, PulmonaryUncertainty

Identifiers

PMID25340701
PMCPMC4207742

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.